451 related articles for article (PubMed ID: 15653136)
1. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery.
Chong CS; Cao M; Wong WW; Fischer KP; Addison WR; Kwon GS; Tyrrell DL; Samuel J
J Control Release; 2005 Jan; 102(1):85-99. PubMed ID: 15653136
[TBL] [Abstract][Full Text] [Related]
2. Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses.
Lutsiak ME; Kwon GS; Samuel J
J Pharm Pharmacol; 2006 Jun; 58(6):739-47. PubMed ID: 16734975
[TBL] [Abstract][Full Text] [Related]
3. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells.
Elamanchili P; Lutsiak CM; Hamdy S; Diwan M; Samuel J
J Immunother; 2007; 30(4):378-95. PubMed ID: 17457213
[TBL] [Abstract][Full Text] [Related]
4. Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits.
Isaguliants MG; Kadoshnikov YP; Kalinina TI; Smirnov VD; Wahren B
Biochemistry (Mosc); 1998 May; 63(5):551-8. PubMed ID: 9632891
[TBL] [Abstract][Full Text] [Related]
5. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
[TBL] [Abstract][Full Text] [Related]
6. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination.
Wang D; Molavi O; Lutsiak ME; Elamanchili P; Kwon GS; Samuel J
J Pharm Pharm Sci; 2007; 10(2):217-30. PubMed ID: 17706180
[TBL] [Abstract][Full Text] [Related]
7. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice.
Kuhöber A; Pudollek HP; Reifenberg K; Chisari FV; Schlicht HJ; Reimann J; Schirmbeck R
J Immunol; 1996 May; 156(10):3687-95. PubMed ID: 8621903
[TBL] [Abstract][Full Text] [Related]
8. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells.
Elamanchili P; Diwan M; Cao M; Samuel J
Vaccine; 2004 Jun; 22(19):2406-12. PubMed ID: 15193402
[TBL] [Abstract][Full Text] [Related]
9. [Humoral and cellular immunogenecity of genetic vaccine on core gene of hepatitis B virus in mice].
Huang Z; Lu S; Liu N
Zhonghua Yi Xue Za Zhi; 1999 Jun; 79(6):456-9. PubMed ID: 11715443
[TBL] [Abstract][Full Text] [Related]
10. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes.
Schödel F; Peterson D; Hughes J; Wirtz R; Milich D
J Biotechnol; 1996 Jan; 44(1-3):91-6. PubMed ID: 8717391
[TBL] [Abstract][Full Text] [Related]
11. Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B.
Jaganathan KS; Singh P; Prabakaran D; Mishra V; Vyas SP
J Pharm Pharmacol; 2004 Oct; 56(10):1243-50. PubMed ID: 15482638
[TBL] [Abstract][Full Text] [Related]
12. Development of hepatitis B oral vaccine using B-cell epitope loaded PLG microparticles.
Rajkannan R; Dhanaraju MD; Gopinath D; Selvaraj D; Jayakumar R
Vaccine; 2006 Jun; 24(24):5149-57. PubMed ID: 16713035
[TBL] [Abstract][Full Text] [Related]
13. Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine.
Xu W; Chu Y; Zhang R; Xu H; Wang Y; Xiong S
Virology; 2005 Apr; 334(2):255-63. PubMed ID: 15780875
[TBL] [Abstract][Full Text] [Related]
14. The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice.
Chen X; Lai J; Pan Q; Tang Z; Yu Y; Zang G
Vaccine; 2010 May; 28(23):3913-9. PubMed ID: 20394723
[TBL] [Abstract][Full Text] [Related]
15. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
Jaganathan KS; Vyas SP
Vaccine; 2006 May; 24(19):4201-11. PubMed ID: 16446012
[TBL] [Abstract][Full Text] [Related]
16. HBcAg18-27 epitope fused to HIV-Tat 49-57 adjuvanted with CpG ODN induces immunotherapeutic effects in transgenic mice.
Wang S; Han Q; Zhang N; Chen J; Liu Z; Zhang G; Li Z
Immunol Lett; 2010 Jan; 127(2):143-9. PubMed ID: 19883689
[TBL] [Abstract][Full Text] [Related]
17. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
[TBL] [Abstract][Full Text] [Related]
18. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
[TBL] [Abstract][Full Text] [Related]
19. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
[TBL] [Abstract][Full Text] [Related]
20. Use of a liposome antigen delivery system to alter immune responses in vivo.
Lutsiak CM; Sosnowski DL; Wishart DS; Kwon GS; Samuel J
J Pharm Sci; 1998 Nov; 87(11):1428-32. PubMed ID: 9811501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
